Swiss pharma giant Novartis (NYSE: NVS) announced plans to acquire Anthos Therapeutics, Inc., a cardiometabolic-focused biopharma co-founded with Blackstone Life Sciences in 2019, in a deal valued at up to USD 3.1 billion. The transaction underscores Novartis’ commitment to expanding its pipeline in thrombosis and cardiovascular diseases.
Acquisition Terms
Anthos shareholders will receive an upfront payment of USD 925 million upon closing, expected in H1 2024. Additional regulatory and commercial milestone payments are included. The deal grants Novartis full rights to abelacimab, a novel factor XI inhibitor developed to prevent strokes and thrombosis in atrial fibrillation and cancer patients.
Drug Profile
Abelacimab, licensed exclusively from Novartis, demonstrated superior safety in the AZALEA-TIMI 71 study, reducing major bleeding by 67% and gastrointestinal bleeding by 89% vs. Bayer’s Xarelto (rivaroxaban). The drug is in Phase III trials: LILAC-TIMI 76 (high-risk atrial fibrillation), ASTER, and MAGNOLIA (cancer-related thrombosis), with results due in H2 2026.
Strategic Outlook
The acquisition strengthens Novartis’ position in thrombosis, targeting unmet needs in atrial fibrillation and oncology. Abelacimab’s profile could challenge existing anticoagulants, offering a safer alternative with fewer bleeding risks.-Fineline Info & Tech
